EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Evaluation of Interleukin-22 and Toll-like receptor-2 as an Immunological Biomarkers in Breast Cancer Patients

Ikram Khazal Qasim Al-Hasso

AL-Kindy College Medical Journal · 2024

DOI: 10.47723/3sfb2q82 ↗
AbstractBibliografische Angaben

Abstract

Background: Interleukin-22 is an effector cytokine belongs to the IL-10 family. Signaling of this cytokine control tumor development by boosting cancerous cells growth. Toll-like receptor-2 act key function in activation of tumor cell proliferation besides increasing tumor cell invasion. Objectives: to assess the level and reliability of IL-22 and TLR-2 in patients with breast cancer as a particular diagnostic and prognostic biomarkers in these patients Subjects and Methods: Ninety breast cancer and sixty healthy control women participated in the current study. ELISA was utilized to measure IL-22 and TLR-2 in the serum of all participating individuals. Results: The results revealed a significantly higher IL-22 concentrations in patients with breast cancer compared to controls (169.1±43.6 ng/L vs. 82.1±19.5 ng/L (P = 0.010)).Patients in Stage-IV and Grades -2 and -3 demonstrated elevated IL-22 concentrations (239±65.1 ng/L besides 201.2±36 ng/L and 321.2±62.6 ng/L respectively), while there is no significant differences in the concentrations of TLR-2 between patients (for different stages and grades) and control (39.1±11.2 ng/ml vs. 32.3±10.7 ng/ml (P = 0.062). Conclusions: Increased serum concentrations of IL-22 in patients with breast cancer with higher concentration in advanced stages. This might confirm a potential value of this cytokine as a marker in the pathogenesis of the disease and its promising role as new diagnostic tools of this cancer. TLR-2 shows non-significant difference in the concentration in patients with breast cancer as compared to control group.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →